Online inquiry

IVTScrip™ mRNA-Anti-TNF, TNFRSF1B-Fc(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ15325MR)

This product GTTS-WQ15325MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets TNF gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000594.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7124
UniProt ID P01375
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNF, TNFRSF1B-Fc(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ15325MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ923MR IVTScrip™ mRNA-Anti-EGFR, ABBV-321(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ABBV-321
GTTS-WQ10486MR IVTScrip™ mRNA-Anti-CGRP, LY-2951742(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA LY-2951742
GTTS-WQ3322MR IVTScrip™ mRNA-Anti-lukG&lukH, ASN-100(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ASN-100
GTTS-WQ13445MR IVTScrip™ mRNA-Anti-TNFRSF10B, PRO95780(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA PRO95780
GTTS-WQ14500MR IVTScrip™ mRNA-Anti-CNR1, RYI-018(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA RYI-018
GTTS-WQ6057MR IVTScrip™ mRNA-Anti-IL6, CNTO 136(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CNTO 136
GTTS-WQ10885MR IVTScrip™ mRNA-Anti-IL1A, MABp1(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MABp1
GTTS-WQ1846MR IVTScrip™ mRNA-Anti-IL17A, AG1-25(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AG1-25
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW